Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?

Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?

Mantle cell lymphoma (MCL), a type of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13q32) translocation, is a clinically heterogenous disease which can range from indolent to highly aggressive. Numerous prognostic factors have been identified, including blastoid histology, the Mantle C...

Full description

Bibliographic Details
Main Authors: Lindsay Hammons, Timothy S. Fenske
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Journal of Personalized Medicine
Subjects:
mantle cell lymphoma
non-Hodgkin lymphoma
minimal residual disease
risk-adapted therapy
Online Access:https://www.mdpi.com/2075-4426/12/7/1134

Similar Items

Similar Items